The Use of Levomepromazine, a.k.a. Methotrimeprazine, a.k.a. Nozinan, in Child and Adolescent Psychiatry
DOI:
https://doi.org/10.12970/2310-8231.2021.09.07Keywords:
Levomepromazine, methotrimeprazine, Nozinan, child adolescent psychiatry, tardive dyskinesiaAbstract
Levomepromazine is rarely used in child and adolescent psychiatry. Four cases are described where extreme behavioural disturbance responded favourably and promptly to oral prescription. Two additional cases are described where ceasing levomepromazine led to early signs of what was probably tardive dyskinesia, resolving completely.
References
Brayfield A, Ed. Martindale: The complete drug reference. [Internet]. 39th ed. London: Pharmaceutical Press; 2017. Levomepromazine. [cited 2020 Jan 11]. Available from: Books@Ovid.
National Institute for Health and Care Excellence. 2012-2013 British National Formulary for Children. Antipsychotic drugs. (accessed 4 July 2019).
Snoek A, et al. Levomepromazine for difficult sedation in pediatric intensive care. Journal of Pediatric Intensive Care 2014; 3(2): 53-57.
Gerlach M, Mehler-Wex C, Schimmelmann BG. Antipsychotics. In: Gerlach M, Warnke A, Greenhill L. Psychiatric drugs in children and adolescents: Basic pharmacology and practical applications. Wein:Springer-Verlag 2014; pp. 157-158. https://doi.org/10.1007/978-3-7091-1501-5_5
van der Zwaan S, et al. Additional use of methotrimeprazine for treating refractory agitation in pediatric patients. Intensive Care Medicine 2012; (1): 175-176. https://doi.org/10.1007/s00134-011-2414-y
